$MMSI (Merit Medical Systems, Inc.)

$MMSI {{ '2016-07-06T16:01:28+0000' | timeago}} • Announcement

$MMSI said the effect of the DFINE acquisition on $MMSI's non-GAAP earnings for the balance of 2016 is expected to be neutral due to business restructuring and consolidation expenses and is expected to be dilutive on a GAAP basis by $0.24-$0.26 per share due to intangible amortization and one-time reorganization costs.

$LMNX {{ '2017-07-24T14:45:10+0000' | timeago}} • Announcement

$LMNX has received FDA clearance for its Aries C. difficile Assay, a method for rapid detection of toxigenic agents. The Aries system is designed to run in multiple laboratory shifts.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$MASI {{ '2017-06-30T12:41:36+0000' | timeago}} • Announcement

Medical technology firm $MASI entered into a partnership with Midmark Corp. for enhancing the accuracy and efficiency of vital signs acquisition in the clinical space. Under the deal, Masimo’s SET pulse oximetry technology is an available option with Midmark's IQvitals Zone. The combination provides accurate and real-time vital signs information.

$LIVN {{ '2017-06-29T15:56:55+0000' | timeago}} • Announcement

$LIVN received FDA approval of its VNS Therapy system in patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$MMSI {{ '2017-06-22T16:08:44+0000' | timeago}} • Announcement

$MMSI received 513(f)(2) (de novo) classification from the FDA to expand indication for $MMSI's Embosphere Microspheres. The indication now includes prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).

$LIVN {{ '2017-06-21T14:06:24+0000' | timeago}} • Announcement

$LIVN said its latest VNS Therapy systems received FDA approval for expanded MRI labeling, affirming VNS Therapy as the only epilepsy device approved by the FDA for MRI scans. This ensures VNS patients with latest technology may visit any MRI center in US and have access to more than 90% of scans routinely performed on patients with epilepsy.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$MDT {{ '2017-06-19T11:01:15+0000' | timeago}} • Announcement

$MDT said its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA Europace-Cardiostim 2017.

$LIVN {{ '2017-06-12T14:07:22+0000' | timeago}} • Announcement

$LIVN announced the appointment of Keyna Skeffington as SVP and General Counsel. She most recently served as VP of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at Medtronic PLC.

$NUVA {{ '2017-06-01T12:44:03+0000' | timeago}} • Announcement

$NUVA appointed Skip Kiil as EVP, International. In this role, Kiil will oversee the company's international operations, reporting to NuVasive's chairman and CEO, Gregory Lucier, and serving on the company's executive leadership team.

$MDT {{ '2017-05-25T14:14:38+0000' | timeago}} • Infographic

$MDT Medtronic Plc. Earnings AlphaGraphics: Q4 2017 highlights

$MDT {{ '2017-05-25T12:41:07+0000' | timeago}} • Webcast

$MDT expects FY18 to have operating margin improvement, with greater strength in 2H18. GM on a constant currency basis is expected to be flat to slightly improve throughout FY18, with modest pricing pressure offset by operating improvement. $MDT also expects currency to negatively affect GM in 1H18, with a greater impact in 1Q18 than in 2Q18.

$MDT {{ '2017-05-25T12:37:30+0000' | timeago}} • Webcast

For FY18, $MDT expects Cardiac & Vascular Group to grow in the range of 5-6%, Minimally Invasive Therapies Group to grow in the range of 3-4%, Restorative Therapies Group to grow approx. 4% and Diabetes to grow in the 10-12% range. Additionally, total $MDT revenue growth is expected to be similar to the annual range.

$MDT {{ '2017-05-25T12:20:51+0000' | timeago}} • Webcast

Geographically, $MDT reported balanced performance in 4Q17, with mid single digit growth in the US and non-US developed markets. The company also reported double digit growth in emerging markets.

$MDT {{ '2017-05-25T12:16:50+0000' | timeago}} • Webcast

$MDT stated that the integration of Covidien progressed as planned and the company has realized over $600MM in synergy savings in FY17. The company is also on track to deliver the goal of $850MM of total cost savings by the end of FY18.

$MDT {{ '2017-05-25T11:22:16+0000' | timeago}} • Announcement

In FY18, $MDT expects constant currency revenue growth to be in the range of 4% to 5%. Medtronic sees full-year non-GAAP diluted EPS to grow by 9-10%. Fiscal year guidance does not include the impact of the divestiture of a portion of its Patient Monitoring and Recovery division to $CAH, expected to close in 2Q18.

Recent Transcripts

CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
NURO (NeuroMetrix Inc.)
Thursday, July 20 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MZOR (Mazor Robotics Ltd.)
Wednesday, May 10 2017 - 12:30pm
NBIX (Neurocrine Biosciences Inc.)
Tuesday, May 9 2017 - 9:00pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
PODD (Insulet Corporation)
Monday, May 8 2017 - 8:30pm
NVAX (Novavax, Inc.)
Monday, May 8 2017 - 8:30pm
OFIX (Orthofix International N.V.)
Thursday, May 4 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, May 3 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
NVDQ (Novadaq Technologies Inc.)
Wednesday, May 3 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
LMNX (Luminex Corporation)
Monday, May 1 2017 - 8:30pm
MDXG (MiMedx Group, Inc.)
Friday, April 28 2017 - 2:30pm
MMSI (Merit Medical Systems, Inc.)
Thursday, April 27 2017 - 9:00pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
LMAT (LeMaitre Vascular, Inc.)
Wednesday, April 26 2017 - 9:00pm

AlphaGraphics you may like